Literature DB >> 22000485

Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity.

Jinzhou Zhu1, Jing Zhang, Lin Zhang, Run Du, Di Xiang, Mingyuan Wu, Ruiyan Zhang, Wei Han.   

Abstract

Doxorubicin (DOX) is a potent anticancer drug, which is widely used in the treatments of a variety of solid and hematopoietic tumours, but its use is limited by its cardiotoxicity and dose-dependent congestive heart failure. After we found the high expression of interleukin-1 receptor I (IL-1RI) gene in mice cardiac tissues with DOX-induced cardiotoxicity, we assumed interleukin-1 (IL-1) signaling might mediate acute DOX-induced cardiotoxicity. In this report, Balb/c mice were intraperitoneally injected with different dosage of DOX followed by different days of study. We found both IL-1β and interleukin-1 receptor antagonist (IL-1Ra) concentrations in serum were highly induced after DOX treatment, associated with increased IL-1RI expression in cardiac tissues. Furthermore, IL-1 signaling was found to express higher with the increased dosage of DOX treatment. Histology score of cardiac tissues showed obvious cardiac damage after DOX treatment, while assessment with the Spearman rank correlation coefficient showed that histology score was closely correlated with IL-1β and IL-1Ra concentrations in serum and IL-1RI expression in cardiac tissue. Our results reveal a potential role of IL-1 signaling in acute DOX-induced cardiotoxic injury and lead to an assumption that this signal system might be a potential candidate agent that inhibits cardiomyocyte-toxicity in DOX-exposed patients. Copyright Â
© 2011. Published by Elsevier SAS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000485     DOI: 10.1016/j.biopha.2011.06.005

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  23 in total

1.  Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse.

Authors:  Carlo Marchetti; Stefano Toldo; Jeremy Chojnacki; Eleonora Mezzaroma; Kai Liu; Fadi N Salloum; Andrea Nordio; Salvatore Carbone; Adolfo Gabriele Mauro; Anindita Das; Ankit A Zalavadia; Matthew S Halquist; Massimo Federici; Benjamin W Van Tassell; Shijun Zhang; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2015-07       Impact factor: 3.105

Review 2.  Targeting interleukin-1 in heart failure and inflammatory heart disease.

Authors:  Benjamin W Van Tassell; Juan M Valle Raleigh; Antonio Abbate
Journal:  Curr Heart Fail Rep       Date:  2015-02

3.  Doxorubicin-loaded silk films: drug-silk interactions and in vivo performance in human orthotopic breast cancer.

Authors:  F Philipp Seib; David L Kaplan
Journal:  Biomaterials       Date:  2012-08-24       Impact factor: 12.479

Review 4.  The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin.

Authors:  Zaid H Maayah; Shingo Takahara; Jason R B Dyck
Journal:  Arch Toxicol       Date:  2020-08-27       Impact factor: 5.153

5.  Self-assembling doxorubicin silk hydrogels for the focal treatment of primary breast cancer.

Authors:  F Philipp Seib; Eleanor M Pritchard; David L Kaplan
Journal:  Adv Funct Mater       Date:  2013-01-07       Impact factor: 18.808

6.  Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice.

Authors:  Zaid H Maayah; Abrar S Alam; Shingo Takahara; Shubham Soni; Mourad Ferdaoussi; Nobutoshi Matsumura; Beshay N Zordoky; David D Eisenstat; Jason R B Dyck
Journal:  FEBS Lett       Date:  2021-05-06       Impact factor: 3.864

Review 7.  Inflammasome as a Therapeutic Target for Cancer Prevention and Treatment.

Authors:  Huyen Trang Ha Thi; Suntaek Hong
Journal:  J Cancer Prev       Date:  2017-06-30

8.  The lack of functional DNMT2/TRDMT1 gene modulates cancer cell responses during drug-induced senescence.

Authors:  Dominika Bloniarz; Jagoda Adamczyk-Grochala; Anna Lewinska; Maciej Wnuk
Journal:  Aging (Albany NY)       Date:  2021-06-17       Impact factor: 5.682

9.  Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin.

Authors:  John Wong; Logan B Smith; Eli A Magun; Thomas Engstrom; Kirsten Kelley-Howard; Dakshina M Jandhyala; Cheleste M Thorpe; Bruce E Magun; Lisa J Wood
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

10.  Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.

Authors:  Chiharu Yokoyama; Takuma Aoyama; Takahiro Ido; Akemi Kakino; Takeru Shiraki; Toshiki Tanaka; Kazuhiko Nishigaki; Aiko Hasegawa; Yoshiko Fujita; Tatsuya Sawamura; Shinya Minatoguchi
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.